Novel Allergic Rhinitis Nasal Spray Shows Promise in Phase 3 Trial

By March 29, 2017

Results showed that GSP 301 was tied to statistically significant improvements from baseline for the primary endpoint when compared to placebo (P<0.001), olopatadine (P=0.028), and mometasone (P=0.019).

Odactra Approved for House Dust Mite Allergies

By March 02, 2017

Odactra provides patients an alternative treatment to allergy shots.